<?xml version="1.0" encoding="UTF-8"?>
<ref id="B74-molecules-26-00438">
 <label>74.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Latif</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Ashraf</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Basit</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ghaffar</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Zafar</surname>
    <given-names>M.S.</given-names>
   </name>
   <name>
    <surname>Saeed</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Meo</surname>
    <given-names>S.A.</given-names>
   </name>
  </person-group>
  <article-title>Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: Discovery and clinical developments</article-title>
  <source>RSC Adv.</source>
  <year>2018</year>
  <volume>8</volume>
  <fpage>16470</fpage>
  <lpage>16493</lpage>
  <pub-id pub-id-type="doi">10.1039/C8RA01934G</pub-id>
 </element-citation>
</ref>
